JonesResearch initiated coverage of Theravance Biopharma (TBPH) with a Buy rating and $24 price target The company’s ampreloxetine is in a Phase 3 study for neurogenic orthostatic hypotension secondary to multiple systemic atrophy, the analyst tells investors in a research note. The firm believes the company is advancing a “potential game-changer” for neurogenic orthostatic hypotension secondary to multiple systemic atrophy. Jones believes Theravance’s near-term economics of its commercial pulmonary franchise are unappreciated at current share levels.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Promising Market Opportunity for Theravance Biopharma: Buy Rating on Ampreloxetine’s Potential in MSA Treatment
- Theravance Biopharma Settles Patent Litigation with Eugia
- Theravance Biopharma’s Hold Rating: Balancing Cash Influx with Long-term Growth Uncertainty
- Theravance Biopharma’s Strategic Moves and Growth Potential Justify Buy Rating
- Theravance Biopharma Sells Trelegy Royalty Interest to GSK